| Literature DB >> 34940700 |
Jieyi Long1,2, Yaqi Chen3, Weihao Chen1,2, Junfeng Wang1, Xuefeng Zhou1, Bin Yang1, Yonghong Liu1,2.
Abstract
Three novel cyclic hexapeptides, sclerotides C-E (1-3), and a new lipodepsipeptide, scopularide I (4), together with a known cyclic hexapeptide sclerotide A (5), were isolated from fermented rice cultures of a soft coral-derived fungus: Aspergillus sclerotiorum SCSIO 41031. The structures of the new peptides were determined by 1D and 2D NMR spectroscopic analysis, Marfey's method, ESIMS/MS analysis, and single crystal X-ray diffraction analysis. Scopularide I (4) exhibited acetylcholinesterase inhibitory activity with an IC50 value of 15.6 μM, and weak cytotoxicity against the human nasopharyngeal carcinoma cell line HONE-EBV with IC50 value of 10.1 μM.Entities:
Keywords: AChE inhibitory; Aspergillus sclerotiorum; lipodepsipeptide; nasopharyngeal carcinoma; sclerotides
Mesh:
Substances:
Year: 2021 PMID: 34940700 PMCID: PMC8703611 DOI: 10.3390/md19120701
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–5.
1H and 13C NMR data for 1 and 2 (700, 175 MHz, DMSO-d6, TMS, δ ppm).
| Position | Sclerotide C (1) | Position | Sclerotide D (2) | ||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| Thr | 1 | 170.3 | Ser | 1 | 169.7 | ||
| 2 | 59.0 | 4.32, m | 2 | 56.8 | 4.55, td (7.2, 4.2) | ||
| 3 | 65.5 | 4.44, m | 3 | 60.7 | 4.04, dd (11.2, 8.7) | ||
| 4 | 20.8 | 1.17, d (6.4) | 3.96, dd (11.3, 4.3) | ||||
| NH | 7.33, d (8.4) | NH | 7.13, d (8.1) | ||||
| Ala | 5 | 172.6 | Ala | 4 | 172.5 | ||
| 6 | 49.6 | 4.22, m | 5 | 49.2 | 4.25, m | ||
| 7 | 16.7 | 1.28, d (7.3) | 6 | 16.3 | 1.25, d (7.3) | ||
| NH | 8.74, d (6.1) | NH | 8.62, d (6.5) | ||||
| Phe | 8 | 171.5 | Phe | 7 | 171.8 | ||
| 9 | 54.4 | 4.63, “q” like (7.6) | 8 | 54.5 | 4.53, “q” like (7.6) | ||
| 10 | 35.6 | 2.89, dd (14.1, 7.9) | 9 | 35.1 | 2.93, dd (14.0, 7.3) | ||
| 2.93, dd (14.1, 7.1) | 2.88, dd (14.0, 7.9) | ||||||
| 11 | 137.6 | 10 | 137.5 | ||||
| 12 | 129.0 | 7.20, d (7.4) | 11 | 129.0 | 7.20, d (7.2) | ||
| 13 | 128.1 | 7.24, t (7.4) | 12 | 128.1 | 7.23, m | ||
| 14 | 126.3 | 7.18, t (7.4) | 13 | 126.2 | 7.17, m | ||
| 15 | 128.1 | 7.24, t (7.4) | 14 | 128.1 | 7.23, m | ||
| 16 | 129.0 | 7.20, d (7.4) | 15 | 129.0 | 7.20, d (7.2) | ||
| NH | 8.43, d (7.5) | NH | 8.26, d (7.0) | ||||
| BASE | 17 | 168.8 | Ser | 16 | 170.8 | ||
| 18 | 54.4 | 4.51, td (7.2, 4.2) | 17 | 59.2 | 4.18, q (5.8) | ||
| 19 | 63.0 | 4.26, dd, (11.3, 7.9) | 18 | 60.8 | 3.70, d (5.7) | ||
| 4.31, m | |||||||
| 39 | 172.1 | NH | 8.65, d (5.5) | ||||
| 40 | 28.6 | 2.45, ovl a | |||||
| 41 | 28.6 | 2.45, ovl a | |||||
| 42 | 173.4 | ||||||
| NH | 8.98, d (6.2) | ||||||
| AA | 20 | 169.3 | AA | 19 | 169.5 | ||
| 21 | 122.0 | 20 | 119.6 | ||||
| 22 | 129.2 | 7.79, dd (7.8, 1.1) | 21 | 129.1 | 7.96, dd (8.1, 1.1) | ||
| 23 | 122.7 | 7.23, m | 22 | 122.2 | 7.20, m | ||
| 24 | 132.2 | 7.59, ddd (8.2, 7.8, 1.0) | 23 | 132.6 | 7.59, ddd (8.4, 6.6, 1.0) | ||
| 25 | 121.0 | 8.58, d (8.2) | 24 | 119.6 | 8.79, d (8.3) | ||
| 26 | 138.6 | 25 | 139.7 | ||||
| NH | 10.89, s | NH | 11.75, s | ||||
| ∆-Trp | 27 | 163.5 | ∆-Trp | 26 | 163.4 | ||
| 28 | 122.2 | 27 | 121.8 | ||||
| 29 | 125.9 | 7.96, s | 28 | 126.3 | 7.97, s | ||
| 30 | 108.6 | 29 | 108.7 | ||||
| 31 | 127.4 | 30 | 127.4 | ||||
| 32 | 117.7 | 7.76, d (7.8) | 31 | 117.7 | 7.76, d (7.7) | ||
| 33 | 120.4 | 7.16, m | 32 | 120.4 | 7.16, m | ||
| 34 | 122.0 | 7.18, m | 33 | 122.2 | 7.20, m | ||
| 35 | 112.0 | 7.42,d (7.9) | 34 | 111.9 | 7.42, d (7.9) | ||
| 36 | 135.5 | 35 | 135.5 | ||||
| 37-NH | 11.95, d (1.9) | 36-NH | 11.97, d (2.0) | ||||
| 38 | 128.7 | 8,00 d (2.8) | 37 | 128.7 | 8.03, d (2.8) | ||
| NH | 8.79, s | NH | 8.82, s | ||||
a Ovl: overlapped or multiplet with other signals.
Figure 2Key HMBC, 1H-1H COSY, and TOCSY correlations for 1, 3 and 4.
Figure 3ORTEP drawing of compounds 1 and 4.
Figure 4Experimental ECD spectra of compounds 1, 2, and 5.
1H and 13C NMR data for 3 and 4 (700, 175 MHz, DMSO-d6, TMS, δ ppm).
| Position | Sclerotides E (3) | Position | Scopularide I (4) | ||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| Thr | 1 | 169.6 | Val | 1 | 170.8 | ||
| 2 | 57.5 | 4.35, dd (9.4, 3.2) | 2 | 57.7 | 4.09, ovl a | ||
| 3 | 66.2 | 4.17, td (6.5, 3.7) | 3 | 29.6 | 2.07, m | ||
| 4 | 19.9 | 1.01, d (6.4) | 4 | 18.8 | 0.87, ovl a | ||
| 3-OH | 4.80, br s | 5 | 17.4 | 0.86, ovl a | |||
| NH | 7.32, d (8.6) | NH | 7.42, br s | ||||
| Ala | 5 | 171.9 | Ala | 6 | 171.9 | ||
| 6 | 48.1 | 4.47, m | 7 | 48.0 | 4.19, m | ||
| 7 | 16.6 | 1.14, d (7.2) | 8 | 17.5 | 1.22, d (7.1) | ||
| NH | 8.39, d (8.5) | NH | 8.00, d (7.8) | ||||
| Phe | 8 | 170.3 | Leu | 9 | 171.4 | ||
| 9 | 54.4 | 4.55, “q” like | 10 | 51.9 | 4.04, ovl a | ||
| 10 | 35.6 | 2.90, dd (13.7, 7.8) | 11 | 38.7 | 1.49, m | ||
| 3.02, dd (13.8, 7.5) | 12 | 24.2 | 1.64, m | ||||
| 11 | 137.6 | 13 | 23.0 | 0.89, ovl a | |||
| 12 | 129.1 | 7.27, d (7,3) | 14 | 21.0 | 0.81, ovl a | ||
| 13 | 128.1 | 7.25, m | NH | 8.65, d (6.6) | |||
| 14 | 126.3 | 7.2, m | Val | 15 | 171.7 | ||
| 15 | 128.1 | 7.25, m | 16 | 58.8 | 4.05, ovl a | ||
| 16 | 129.1 | 7.27, d (7,3) | 17 | 29.5 | 1.85, m | ||
| NH | 8.31, d (7.8) | 18 | 19.0 | 0.88, ovl a | |||
| Ser | 17 | 170.8 | 19 | 19.1 | 0.88, ovl a | ||
| 18 | 57.8 | 4.23, q (6.8) | NH | 8.07, d (7.6) | |||
| 19 | 61.1 | 3.67, m | Gly | 20 | 169.1 | ||
| 19-OH | 5.15, m | 21 | 42.0 | 4.08, ovl a | |||
| NH | 8.31, d (7.8) | 3.45, dd (17.1, 3.7) | |||||
| AA | 20 | 168.1 | NH | 7.90, dd (6.6, 3.9) | |||
| 21 | 123.1 | HMLA | 22 | 169.9 | |||
| 22 | 129.7 | 7.94, d (7.9) | 23 | 37.5 | 2.53, dd (15.6, 9.6) | ||
| 23 | 129.2 | 7.27, m | 2.24, m | ||||
| 24 | 132.1 | 7.58, ddd (8.4, 6.6, 1.0) | 24 | 75.5 | 4.91, ddd (9.4, 3.8, 2.3) | ||
| 25 | 122.2 | 8.36, m | 25 | 36.3 | 1.67, m | ||
| 26 | 138.3 | 26 | 31.6 | 1.36, m | |||
| NH | 10.86, br s | 1.02, m | |||||
| ADPAT | 27 | 164.2 | 27 | 26.6 | 1.28, ovl a | ||
| 28 | 123.2 | 1.18, ovl a | |||||
| 29 | 126.2 | 7.87, s | 28 | 28.7 | 1.23, ovl a | ||
| 30 | 106.8 | 29 | 28.9 | 1.23, ovl a | |||
| 31 | 125.3 | 30 | 29.3 | 1.23, ovl a | |||
| 32 | 120.7 | 7.34, m | 31 | 31.3 | 1.23, ovl a | ||
| 33 | 120.9 | 7.02, m | 32 | 22.1 | 1.27, ovl a | ||
| 34 | 120.1 | 7.02, m | 33 | 14.0 | 0.85, s | ||
| 35 | 112.6 | 7.34, m | 34 | 14.8 | 0.83, ovl a | ||
| 36 | 135.9 | ||||||
| 37-NH | 10.78, s | ||||||
| 38 | 141.6 | ||||||
| NH | 9.32, s | ||||||
| 39 | 19.8 | 4.05, d (14.7) | |||||
| 40 | 110.9 | ||||||
| 41 | 162.4 | ||||||
| 41-OH | 13.27, s | ||||||
| 42 | 111.5 | ||||||
| 43 | 131.9 | 7.75, d (8.9) | |||||
| 44 | 107.5 | 6.53, d (8.8) | |||||
| 45 | 162.8 | ||||||
| 45-OH | 11.01, s | ||||||
| 46 | 203.3 | ||||||
| 47 | 26.1 | 2.54, s | |||||
a Ovl: overlapped or multiplet with other signals.
Figure 5(+)-HRESIMS/MS fragments of compound 3.
Figure 6Molecular docking of 4 with AChE (PDB code: 2CMF). The binding sites of the molecule 4 (A) with the AChE protein. The 2D interaction details of the predicted binding mode of 4 (B) with the AChE.